Dr. Ahmed A. M. Elnour is a senior researcher at the biotechnology department at IIUM, leading research in biological chemistry applications, mainly beating and understanding cancer. Dr. Elnour has extensive experience with green chemistry, mainly; plant bioactivity and phytochemistry, particularly focusing on Gum Arabic (GA) bioactivity based on three-dimensional (3D) cell culture. Currently working on breast cancer using organ-on-a-chip (OoCs) technology for regenerative and personalized medicine. Dr Elnour was previously served as head of the biochemistry and gum processing department at the Institute of Gum Arabic & Desertification Studies (IGADS), University of Kordofan (KU), Sudan. Dr Elnour served as a lecturer in biochemistry and food science at KU, Sudan, and part-time lecturer in biochemistry and molecular biology at West-Kordofan University (WKU), Sudan, before joining IIUM as a PhD and Postdoctoral Research Fellow (PDF) under Islamic Development Bank (IsDB) merit scholarship. Moreover, Dr Elnour has a biotechnology expert with over 20 years of experience bridging academia and industry. Dr Elnour has an excellent reputation for resolving scientific challenges and improving biotechnological customer satisfaction on industrial platforms. Therefore, Elnour's business strategy for any host institute (HO) is to create pioneer anti-cancer developing drugs that need to be approved using OoCs technology to control cancer expansion worldwide. Following Dr Elnour proposed strategy, will enter into clinical trials to assess the safety and efficacy of leading bioactive compounds before being approved by the Food and Drug Administration (FDA). Hence, OoCs technology is projected to have a global market of $6.13 billion by 2025. Thus, HO urgently needs this to address the core criteria of drug absorption, distribution, metabolism, and excretion. Once established OoCs, technology in HO will certainly avoid many limitations, problems, and unnecessary loading of patients with ineffective drugs. Therefore, Dr. Elnour hopes to set up the first commercial applications of Dr Elnour specialization (OoCs) platform in HO. This will likely be for beating cancer improving cancer patient care by realizing personalized medicine. The OoCs devices can be used to culture patient-derived cells that emulate the biology and physiology of the individual. Consequently, Dr. Elnour's field of specialization positively impacts multiple SDGs, including; SDG-1, SDG-2, SDG-3, SDG-4, SDG-8, SDG-9, SDG-13, and SDG-17. Further information about Dr. Elnour CV in (https://europa.eu/europass/eportfolio/screen/profile?lang=en) and about research and publication (https://orcid.org/my-orcid?orcid=0000-0002-1924-094X).

Last synced: Never